Updates are available Correction dated 2022-04-21
Click to view Correction: https://doi.org/10.1038/s41398-022-01933-x
-
Authors
Garcia-Argibay, Miguel http://orcid.org/0000-0002-4811-2330
du Rietz, Ebba
Lu, Yi http://orcid.org/0000-0001-9933-3654
Martin, Joanna http://orcid.org/0000-0002-8911-3479
Haan, Elis
Lehto, Kelli
Bergen, Sarah E.
Lichtenstein, Paul http://orcid.org/0000-0003-3037-5287
Larsson, Henrik
Brikell, Isabell
-
Funding
Funding for this research was provided by:
Svenska Sällskapet för Medicinsk Forskning (PD20-0036)
Forskningsrådet om Hälsa, Arbetsliv och Välfärd (2019-01172)
Eesti Teadusagentuur (PSG615)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R21MH116188)
Vetenskapsrådet (2018-02599)
Hjärnfonden (FO2021-0115)
- License Information
-
More Information
Article History
Received: 11 November 2021
Revised: 23 March 2022
Accepted: 24 March 2022
First Online: 11 April 2022
Change Date: 21 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41398-022-01933-x
Competing interests
: MG-A, IB, YL, JM, SEB, KL, EH, and PL declare no potential conflicts of interest. HL has served as a speaker for Medice, Evolan Pharma, and Shire/Takeda and has received research grants from Shire/Takeda; all outside the submitted work. EdR has served as a speaker for Shire Sweden, a Takeda Pharmaceuticals company, outside of the submitted work.
